Effect of chinonin on acute hypoxic pulmonary vasoconstriction in Sprague-Dawley rats.
The objective of this study was to determine the influence of chinonin on acute hypoxic pulmonary vasoconstriction (HPV) in Sprague-Dawley (SD) rats and investigate its mechanism. Sixty-five SD rats were divided into five groups at random: six in the control group; six in the hypoxia group; 13 in the group of hypoxia with chinonin; 20 in the group of endothelin-1 (ET-1) with chinonin and 20 in the group of platelet activating factor (PAF) with chinonin. Their mean pulmonary arterial pressures (mPAP) were measured and the concentration of molondialdehyde (MDA) in plasma and the activity of phospholipase A2 (PLA2) of the lung tissues were detected. The PAF and ET-1 levels of plasma and lung homogenates were detected in the control and hypoxia groups. There was evidence of an increase in mPAP, MDA, PAF and ET-1 in the plasma, and activity of PLA2, PAF and ET-1 of the lung tissues when the rats inhaled a 10% mixture of oxygen in nitrogen. It appeared that chinonin may have been inhibiting the action of ET-1 and PAF. Chinonin could have prevented an increase in MPAP caused by hypoxia and inhibited the action of ET-1 and PAF. But chinonin had no influence on the increase in MDA in the plasma and the PLA2 activity of the lungs when hypoxia occurred. Chinonin can reduce HPV, but does not influence normal mPAP. It may do this by blocking the action of ET-1 and/or PAF or others. The definite mechanism needs to be studied further.
Shanghai Medical University, Shanghai First Pulmonology Hospital, PR China.
H P
HP
Li
Z G
ZG
Fu
M
M
Li
Y
Y
Xiang
X M
XM
Xia
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D019332:Endothelin-1 / Q000494:pharmacology; D005260:Female; D016166:Free Radical Scavengers / Q000494:pharmacology*; D006027:Glycosides / Q000494:pharmacology*; D000860:Hypoxia / Q000503:physiopathology*; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D010741:Phospholipases A / Q000378:metabolism; D054467:Phospholipases A2; D010936:Plant Extracts / Q000494:pharmacology*; D010972:Platelet Activating Factor / Q000494:pharmacology; D011652:Pulmonary Circulation / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014661:Vasoconstriction / Q000187:drug effects*; D014966:Xanthenes / Q000494:pharmacology*; D044004:Xanthones
D000893:Anti-Inflammatory Agents; D019332:Endothelin-1; D016166:Free Radical Scavengers; D006027:Glycosides; D010936:Plant Extracts; D010972:Platelet Activating Factor; D014966:Xanthenes; D044004:Xanthones; C013592:mangiferin; D008315:Malondialdehyde; D010741:Phospholipases A; D054467:Phospholipases A2